Dossier assessment
Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation
Added benefit not proven
Project details
- Project no.
- A25-138
- Commission
- Commission awarded on 31.10.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-138
Connected Projects
-
Dossier assessment
Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Avapritinib (advanced systemic mastocytosis) – Assessment according to §35a (para. 1., sentence 11)
Status: Commission completed
-
Dossier assessment
Avapritinib (GIST) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Avapritinib (advanced systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Avapritinib (indolent systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed